Medicare Enrolled
Dr. Laurence Tokaz, M.D.
Medical Oncology · Austin, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Tokaz from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tokaz?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tokaz
Dr. Laurence Tokaz is a medical oncology specialist in Austin, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Tokaz performed 60,248 Medicare services across 2,501 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tokaz received a total of $27,309 from 14 pharmaceutical and/or device companies across 47 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tokaz is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 17% volume in TX
$27,309 industry payments
Medicare Practice Summary
Medicare Utilization ↗60,248
Medicare services
Top 17% in TX for medical oncology
2,501
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,171 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
12,750 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 8,100 | $43 | $136 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
7,100 | $0 | $2 |
| Nivolumab injection (Opdivo) | 7,100 | $21 | $76 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
6,600 | $0 | $5 |
| Paclitaxel chemotherapy injection | 4,680 | $0 | $8 |
| Denosumab injection (Prolia/Xgeva) | 2,160 | $18 | $66 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,899 | $0 | $1 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
1,330 | $4 | $116 |
| Immune globulin infusion (Octagam) This procedure involves the administration of immune globulin medication directly into a vein. It is provided in a non-lyophilized liquid form. |
1,240 | $33 | $234 |
| Anti-nausea injection (Aloxi/palonosetron) | 600 | $1 | $114 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
597 | $2 | $13 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
486 | $8 | $20 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
410 | $8 | $36 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
407 | $10 | $64 |
| Injection, potassium chloride, per 2 meq | 385 | $0 | $1 |
| Immunoglobulin level test A blood test that measures the level of gammaglobulins, which are immune system proteins. |
357 | $9 | $56 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
308 | $24 | $157 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
307 | $107 | $707 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
257 | $13 | $108 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
242 | $88 | $368 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
217 | $2 | $300 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
178 | $6 | $31 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
174 | $2 | $19 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
156 | $1 | $6 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
124 | $23 | $161 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
110 | $10 | $75 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
107 | $137 | $496 |
| Immunoglobulin light chain measurement A blood test that measures the levels of immunoglobulin light chains, which are proteins produced by plasma cells. |
104 | $17 | $60 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
97 | $6 | $431 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
96 | $50 | $313 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
80 | $18 | $99 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
80 | $11 | $96 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
80 | $60 | $211 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
79 | $16 | $100 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
73 | $53 | $344 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
73 | $1 | $7 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 72 | $20 | $128 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
64 | $60 | $247 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
59 | $26 | $256 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 59 | $316 | $1,722 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
57 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
57 | $6 | $34 |
| Reticulated platelet measurement A blood test that measures the level of young, newly formed platelets in the body. |
56 | $35 | $143 |
| Iron level test | 54 | $6 | $27 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
54 | $9 | $35 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
54 | $136 | $500 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
53 | $13 | $60 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
53 | $46 | $289 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
52 | $1 | $9 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 52 | $135 | $3,675 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
42 | $29 | $247 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
37 | $16 | $94 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
37 | $93 | $357 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
28 | $27 | $145 |
| Beta-2 microglobulin level test A blood test that measures the level of beta-2 microglobulin, a protein produced by cells in the body. |
27 | $16 | $96 |
| Serum protein measurement A blood test that measures the total amount of protein in the serum. It helps evaluate overall health and nutritional status. |
20 | $11 | $99 |
| Immunologic analysis of serum A laboratory test that uses immunologic techniques to analyze components in a blood serum sample. |
20 | $29 | $108 |
| Serum immunofixation test A laboratory test that analyzes a blood serum sample to identify specific abnormal proteins. The procedure uses an immunologic technique to detect and characterize these proteins. |
20 | $22 | $160 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 18 | $91 | $657 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
17 | $16 | $80 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
17 | $69 | $264 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
14 | $1,228 | $4,802 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
12 | $43 | $250 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
25.1% high complexity
69.5% medium
5.4% routine
Industry Payment Transparency
Open Payments through 2023 ↗$27,309
Total received (2018-2023)
Avg $4,552/year across 6 years
Top 28% in TX for medical oncology
14
Companies
47
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$19,439 (71.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$7,549 (27.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$321 (1.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2023
$70
2022
$96
2021
$129
2020
$47
2019
$14,857
2018
$12,110
Payments by company (2023)
Consulting
Speaking
Meals & Travel
Research
Takeda Pharmaceuticals U.S.A., Inc.
$19,282
Kite Pharma, Inc.
$5,014
Amgen Inc.
$2,535
Genentech USA, Inc.
$123
Janssen Biotech, Inc.
$112
E.R. Squibb & Sons, L.L.C.
$56
Celgene Corporation
$55
AstraZeneca Pharmaceuticals LP
$39
Novartis Pharmaceuticals Corporation
$23
EMD Serono, Inc.
$16
Seagen Inc.
$16
Puma Biotechnology, Inc.
$15
Gilead Sciences, Inc.
$12
AMAG Pharmaceuticals, Inc.
$12
Top 3 companies account for 98.2% of total payments
Associated products mentioned in payments ›
BAVENCIO · Blincyto · FERAHEME · IMBRUVICA · NINLARO · OPDIVO · PADCEV · PROMACTA · Pomalyst · REBLOZYL · Rituxan · Yescarta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (71%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Equivalent to $45 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
25
Per 100K population
1.9
County median income
$97,169
Nearest hospital
AUSTIN OAKS HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2023 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Tokaz is a mixed practice specialist, with above-average Medicare volume (top 17% in TX), with speaking/promotional industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Tokaz experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Tokaz performed 12,750 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tokaz receive payments from pharmaceutical companies?
Yes. Dr. Tokaz received a total of $27,309 from 14 companies across 47 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tokaz's costs compare to other medical oncologists in Austin?
Dr. Tokaz's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tokaz) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Austin
Browse medical oncologists in Austin ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
Kite Pharma, Inc. Payments to Doctors
See all physicians who received payments from Kite Pharma, Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology